Table 2.
Summary of the pre-meeting PGx implementation survey (36 responding of 73 invited).
| Question (N=total) | Percent | |
|---|---|---|
| Type of PGx Implementation (N=40)1 | 57 | Clinical and Research |
| 28 | Clinical Only | |
| 15 | Research Only | |
| Responding Institution (36) | 53 | Academia |
| 22 | Non-academic setting | |
| 14 | Hospital | |
| 11 | Other healthcare setting | |
| Triggers Prompting PGx Test Orders (N=40) | 35 | Reactive |
| 65 | Pre-emptive | |
| Type of Alert Prompting PGx Test Order or Notification of PGx Test Results (N=39) | 51 | Active and Passive |
| 31 | Active (i.e. alert and/or specific message sent) | |
| 18 | Passive (i.e. the test order was available on demand only) | |
| Filing for 3rd Party Reimbursement for PGx Tests (N=37) | 60 40 |
Filing Not Filing |
| External Resources or Knowledgebases Used (N=36) | 94 | CPIC |
| 78 | PharmGKB | |
| 19 | IGNITE Spark | |
| 17 | ClinVar | |
| Genotyping Platforms Used (N=47)* | 38 | Real-Time PCR Systems |
| 17 | DMET Panel | |
| 13 | ADME Panel | |
| 32 | Other | |
| PGx Gene-Drug Pair Currently Tested (N=35) | 91 | CYP2C19-Clopidogrel |
| 86 | SLCO1B1-Simvastatin | |
| 83 | CYP2C9/VKORC1-Warfarin | |
| 80 | TPMT-Thiopurines | |
| 74 | CYP2D6-Codeine | |
| 71 | CYPG2C19 and/or CYP2D6-Antidepressants | |
| 60 | DPYD-Fluorouracil, capecitabine | |
| 43 | UGT1A1-Irinotecan, Belinostat, Nilotinib, Pazopanib, Erlotinib, Atazanavir, Abacavir, Indacaterol | |
| 40 | IFNL3-Ribavarin, peginterferon | |
| 34 | HLAB-Abacavir | |
| 31 | HLA-Allopurinol, Carbamazepine, Phenytoin |
1
Some participants reported on more than one project.
2
Some projects used more than one platform.